CN1500518A - Freeze drying powder containing red ginseng and accessory piece for injection - Google Patents
Freeze drying powder containing red ginseng and accessory piece for injection Download PDFInfo
- Publication number
- CN1500518A CN1500518A CNA021493685A CN02149368A CN1500518A CN 1500518 A CN1500518 A CN 1500518A CN A021493685 A CNA021493685 A CN A021493685A CN 02149368 A CN02149368 A CN 02149368A CN 1500518 A CN1500518 A CN 1500518A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- add
- crude drug
- time
- cold preservation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 17
- 239000007924 injection Substances 0.000 title claims abstract description 17
- 238000004108 freeze drying Methods 0.000 title claims abstract description 6
- 239000000843 powder Substances 0.000 title abstract description 7
- 235000002789 Panax ginseng Nutrition 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 123
- 238000010828 elution Methods 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000011347 resin Substances 0.000 claims abstract description 11
- 229920005989 resin Polymers 0.000 claims abstract description 11
- 239000000706 filtrate Substances 0.000 claims abstract description 9
- 241000173529 Aconitum napellus Species 0.000 claims abstract description 7
- 229940023019 aconite Drugs 0.000 claims abstract description 7
- 238000005406 washing Methods 0.000 claims abstract 3
- 241000208340 Araliaceae Species 0.000 claims description 25
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 25
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 25
- 235000008434 ginseng Nutrition 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 17
- 239000000796 flavoring agent Substances 0.000 claims description 16
- 235000019634 flavors Nutrition 0.000 claims description 16
- 238000004321 preservation Methods 0.000 claims description 16
- 239000000469 ethanolic extract Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- XFSBVAOIAHNAPC-XTHSEXKGSA-N 16-Ethyl-1alpha,6alpha,19beta-trimethoxy-4-(methoxymethyl)-aconitane-3alpha,8,10alpha,11,18alpha-pentol, 8-acetate 10-benzoate Chemical compound O([C@H]1[C@]2(O)C[C@H]3[C@@]45C6[C@@H]([C@@]([C@H]31)(OC(C)=O)[C@@H](O)[C@@H]2OC)[C@H](OC)[C@@H]4[C@]([C@@H](C[C@@H]5OC)O)(COC)CN6CC)C(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-XTHSEXKGSA-N 0.000 claims description 6
- XFSBVAOIAHNAPC-UHFFFAOYSA-N Aconitin Natural products CCN1CC(C(CC2OC)O)(COC)C3C(OC)C(C(C45)(OC(C)=O)C(O)C6OC)C1C32C4CC6(O)C5OC(=O)C1=CC=CC=C1 XFSBVAOIAHNAPC-UHFFFAOYSA-N 0.000 claims description 6
- 229940039750 aconitine Drugs 0.000 claims description 6
- STDXGNLCJACLFY-UHFFFAOYSA-N aconitine Natural products CCN1CC2(COC)C(O)CC(O)C34C5CC6(O)C(OC)C(O)C(OC(=O)C)(C5C6OC(=O)c7ccccc7)C(C(OC)C23)C14 STDXGNLCJACLFY-UHFFFAOYSA-N 0.000 claims description 6
- 238000005202 decontamination Methods 0.000 claims description 6
- 230000003588 decontaminative effect Effects 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000012856 packing Methods 0.000 claims description 4
- 229930013930 alkaloid Natural products 0.000 claims description 3
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 claims description 3
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 claims description 3
- 229930182490 saponin Natural products 0.000 claims description 3
- 150000007949 saponins Chemical class 0.000 claims description 3
- 235000017709 saponins Nutrition 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 3
- 239000012535 impurity Substances 0.000 abstract description 3
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 238000000605 extraction Methods 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 8
- 241000700159 Rattus Species 0.000 description 6
- 241000976983 Anoxia Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 206010002660 Anoxia Diseases 0.000 description 3
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- 239000009798 Shen-Fu Substances 0.000 description 3
- 206010049771 Shock haemorrhagic Diseases 0.000 description 3
- 230000007953 anoxia Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 2
- 244000166550 Strophanthus gratus Species 0.000 description 2
- 206010044541 Traumatic shock Diseases 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
- 229960003343 ouabain Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000000703 anti-shock Effects 0.000 description 1
- 230000003177 cardiotonic effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses the preparation of freeze dried Shengfu powder for injection. The preparation process includes separated alcohol extraction of red sage and aconite root piece, recovering alcohol, macroporous resin treatment of the filtrate, water washing to eliminate impurity, alcohol elution and freeze drying.
Description
Technical field
The present invention relates to a kind of preparation method of traditional medicine Injectio, particularly relate to the preparation method of joining attached freeze-dried powder.
Background technology
Shenfu decoction is the proved recipe in ancient times, especially the classics prescription in the tcm emergency treatment.Traditional decoction has been improved in the prior art and made SHENFU ZHUSHEYE, SHENFU ZHUSHEYE becomes the indispensable medicine of emergency department rapidly because of its determined curative effect, onset in the middle of treatment ischemic shock, cardiovascular and cerebrovascular disease.The ginseng aconite injection preparation that further development quality is stable, controlled, active constituent content is higher is not only the needs of medical practice, also is the needs of Chinese medicine pharmaceutical development.
Summary of the invention
The object of the invention is to provide the preparation method of the attached freeze-dried powder of a seed ginseng.
The present invention seeks to be achieved through the following technical solutions:
Radix Ginseng Rubra 500 weight portion Radix Aconiti Lateralis Preparatas 1000 weight portions
Get Radix Ginseng Rubra and add 50-70% alcohol reflux 2-5 time, each 1-3 hour, add 5-7 for the first time and doubly measure 50-70% ethanol, add 4-6 for the 2-5 time and doubly measure 50-70% ethanol, merge ethanol extract 2-5 time, reclaim ethanol to there not being the alcohol flavor, thin up cold preservation 12-48 hour, filters, filtrate is crossed macroporous resin, washes decontamination with water, reuse 60-80% ethanol elution, collect the 60-80% ethanol elution, reclaim ethanol to there not being the alcohol flavor, be equivalent to crude drug 1-3g/ml, cold preservation 12-48 hour;
Get Radix Aconiti Lateralis Preparata and add 50-70% alcohol reflux 2-5 time, each 1-3 hour, add 4-6 for the first time and doubly measure 50-70% ethanol, the 2-5 time 3-5 doubly measures 50-70% ethanol, merges ethanol extract 2-5 time, reclaims ethanol to there not being the alcohol flavor, thin up cold preservation 12-48 hour, filters, filtrate is crossed macroporous resin, washes decontamination with water, reuse 85-95% ethanol elution, collect the 85-95% ethanol elution, reclaim ethanol to there not being the alcohol flavor, be equivalent to crude drug 3-5g/ml, cold preservation 12-48 hour;
Mix said extracted liquid, stir evenly, add water,, stir evenly, add 0.1-1% active carbon heated and boiled 20-60 minute, put coldly, add water, transfer PH to 4.0-9.0 with mannitol 2-5%, fine straining, packing, lyophilization, promptly.
Macroporous resin model of the present invention is D101, D201, D601, HP-20.
The present invention joins the every ml of attached freeze-dried powder and contains Radix Ginseng total saponins with ginsenoside Re (C
48H
82O
18) meter, must not be less than 2.4mg; Contain aconite alkaloids with aconitine (C
24H
47NO
11) meter, should be 0.3～0.6mg.
It is as follows that the present invention joins the drug efficacy study of attached freeze-dried powder:
One, cardiotonic
1. to the influence of isolated frog heart: injection ginseng attached (lyophilizing) each dosage group (2.5,5.0,10.0,15.0,20.0mg) does not have the significance influence to frog heart heart rate; 2.5,5.0mg can promote myocardial contraction (P＜0.05～0.01) significantly.
2. to the influence of rabbit: injection ginseng attached (lyophilizing) each dosage group (n=4 at systemic heart, 0.5,1.0,2.0g/kg), the result, 2.0 g/kg can significantly increase myocardial contraction, the amplitude amplitude obviously strengthens (P＜0.05～0.01), and myocardial failure (P＜0.01) due to the antagonism aconitine of energy significance.
Two, to the therapeutical effect of hemorrhagic shock animal
1. to the influence of hemorrhagic shock rats: in administration 10min, injection ginseng attached (lyophilizing) each dosage group is consistent with matched group to the influence of rat blood pressure, do not see obvious influence, behind the 20min, injection ginseng attached (lyophilizing) big or middle dosage group shows significant boosting, show that boosting relatively relaxes, low dose of also have certain boosting, but do not have significance; The reduction of middle dosage energy significance antagonism heart rate when 60min, all the other dosage group there was no significant differences show that the recovery to heart rate there is no obvious influence.
2. to the influence of hemorrhagic shock cat blood pressure: after injection ginseng attached (lyophilizing) (0.25,0.5,1.0, the 2.0g/kg) input slight hypotensive effect is arranged, different boostings all appears when reinjecting 0.5g/kg, 1.0g/kg or 2.0g/kg, can obviously raise systolic pressure (1.0g/kg), mean pressure (0.5g/kg and 1.0g/kg), diastolic pressure (0.5g/kg and 2.0g/kg) have significantly Antishock function.
Three, to the influence of traumatic shock mice survival rate
The result shows, the traumatic shock mice that injection ginseng attached (lyophilizing) (n=20,1.25,2.5,5.0g/kg) causes extremity Ischemic Reperfusion has the preventive and therapeutic effect (P＜0.05～0.01) of significance.。
Four, anti-arrhythmia effect
1. to the ARR influence of chloroform induced mice: injection ginseng attached (lyophilizing) (n=20,1.25,2.5,5.0g/kg), chloroform is brought out the antagonism (P＜0.05～0.001) that the mice arrhythmia has highly significant.
2. to the influence of rat ventricular due to the aconitine: injection ginseng attached (lyophilizing) (n=10,0.25,0.5,1.0g/kg), big or middle dosage can the postponement aconitine of significance due to the time of occurrence (min) (P＜0.05～0.01) of rat ventricular.
3. to the ARR influence of Cavia porcellus due to the ouabain: injection ginseng attached (lyophilizing) (0.5,1.0,2.0g/kg), Cavia porcellus arrhythmia due to the ouabain there is in various degree antagonism, the time retardation that VP (chamber early), VT (chamber speed) appear in large, medium and small dosage compares there was no significant difference (P＞0.05) with matched group; Dosage big or middle is significantly postponed (P＜0.05～0.01) to VF (quivering in the chamber), CA (cardiac muscle stops fighting) time of occurrence.
Five, to the influence of animal anoxia enduring and acute myocardial ischemia
1. to the influence of mice normal pressure anoxia enduring: injection ginseng attached (lyophilizing) (1.25,2.5,5.0g/kg) can obviously improve the ability of mice anoxia enduring, makes life span significant prolongation (P＜0.05～0.01).
2. to the influence of isoproterenol load mice anoxia enduring life span: injection ginseng attached (lyophilizing) (n=12,1.25,2.5,5.0g/kg) the equal significance of each dosage group prolongs mice life span (P＜0.05～0.01).
3. to the influence of rat heart muscle ischemia: the result shows, injection ginseng attached (lyophilizing) (0.5,1.0,2.0g/kg) has certain improvement effect to rat heart muscle ischemia due to the pituitrin.
Embodiment 1:
Get Radix Ginseng Rubra 500g and add alcohol reflux 3 times, each 2 hours, add 6 times of amount 60% ethanol for the first time, 2nd, add 5,7 times of amount 65%, 70% ethanol for 3 times, merge 3 times ethanol extract, reclaim ethanol to there not being the alcohol flavor, thin up is to 1000-3000ml, and cold preservation 24 hours is filtered, filtrate is crossed the D101 macroporous resin, water 4000ml flush away impurity, reuse 75% ethanol 3000ml eluting, collect 75% ethanol elution, reclaim ethanol to there not being the alcohol flavor, be equivalent to crude drug 2g/ml, cold preservation 24 hours.
Get Radix Aconiti Lateralis Preparata 1000g and add alcohol reflux 3 times, each 2 hours, add for the first time 6 times of amount 60% ethanol, 2nd, add 5,7 times of amount 65%, 70% ethanol for 3 times, merge 3 times ethanol extract, reclaim ethanol to there not being the alcohol flavor, thin up to thin up to 3000-5000ml, cold preservation 24 hours, filter, filtrate is crossed the D101 macroporous resin, water 8000ml flush away impurity, reuse 90% ethanol 6000ml eluting, collect the 85-95% ethanol elution, reclaim ethanol to there not being the alcohol flavor, be equivalent to crude drug 4g/ml, cold preservation 24 hours.
Mix said extracted liquid, stir evenly, add water to about 5000ml,, stir evenly, add 0.5% active carbon heated and boiled 20-60 minute, put coldly, add water to 5000ml with mannitol 3%, accent PH to 5-7, fine straining, 1000 bottles of packing, lyophilization, promptly.Every ml contains Radix Ginseng total saponins in the ginsenoside Re, must not be less than 2.4mg; Contain aconite alkaloids in aconitine, should be 0.3～0.6mg.
Claims (4)
1, a kind of ginseng aconite injection preparation is characterized in that every ml contains Radix Ginseng total saponins in the ginsenoside Re in the said preparation, must not be less than 2.4mg; Contain aconite alkaloids in aconitine, should be 0.3～0.6mg.
2, the preparation method of ginseng aconite injection preparation as claimed in claim 1 is characterized in that this method is:
Get Radix Ginseng Rubra and add 50-70% alcohol reflux 2-5 time, each 1-3 hour, add 5-7 for the first time and doubly measure 50-70% ethanol, add 4-6 for the 2-5 time and doubly measure 50-70% ethanol, merge ethanol extract 2-5 time, reclaim ethanol to there not being the alcohol flavor, thin up cold preservation 12-48 hour, filters, filtrate is crossed macroporous resin, washes decontamination with water, reuse 60-80% ethanol elution, collect the 60-80% ethanol elution, reclaim ethanol to there not being the alcohol flavor, be equivalent to crude drug 1-3g/ml, cold preservation 12-48 hour;
Get Radix Aconiti Lateralis Preparata and add 50-70% alcohol reflux 2-5 time, each 1-3 hour, add 4-6 for the first time and doubly measure 50-70% ethanol, the 2-5 time 3-5 doubly measures 50-70% ethanol, merges ethanol extract 2-5 time, reclaims ethanol to there not being the alcohol flavor, thin up cold preservation 12-48 hour, filters, filtrate is crossed macroporous resin, washes decontamination with water, reuse 85-95% ethanol elution, collect the 85-95% ethanol elution, reclaim ethanol to there not being the alcohol flavor, be equivalent to crude drug 3-5g/ml, cold preservation 12-48 hour;
Mix said extracted liquid, stir evenly, add water,, stir evenly, add 0.1-1% active carbon heated and boiled 20-60 minute, put coldly, add water, transfer PH to 4.0-9.0 with mannitol 2-5%, fine straining, packing, lyophilization, promptly.
3, preparation method as claimed in claim 2 is characterized in that the macroporous resin model is D101, D201, D601, HP-20 in this method.
4, profit requires 2 or 3 described preparation methoies, it is characterized in that this method is:
Get Radix Ginseng Rubra 500 weight portions and add alcohol reflux 3 times, each 2 hours, add for the first time 6 times of amount 60% ethanol, 2nd, add 5,7 times of amount 65%, 70% ethanol for 3 times, merge 3 times ethanol extract, reclaim ethanol to not having alcohol flavor, thin up, the 2-6 that is equivalent to the crude drug amount doubly, cold preservation 24 hours is filtered, and filtrate is crossed the D101 macroporous resin, washing decontamination with 8 times of crude drug amounts, 75% ethanol elution of 6 times of crude drug amounts of reuse is collected 75% ethanol elution, reclaims ethanol to there not being the alcohol flavor, be equivalent to crude drug 2g/ml, cold preservation 24 hours;
Get Radix Aconiti Lateralis Preparata 1000 weight portions and add alcohol reflux 3 times, each 2 hours, add for the first time 6 times of amount 60% ethanol, 2nd, add 5,7 times of amount 65%, 70% ethanol for 3 times, merge 3 times ethanol extract, reclaim ethanol to not having alcohol flavor, thin up, the 3-5 that is equivalent to the crude drug amount doubly, cold preservation 24 hours is filtered, and filtrate is crossed the D101 macroporous resin, washing decontamination with 8 times of crude drug amounts, 90% ethanol elution of 6 times of crude drug amounts of reuse is collected 90% ethanol elution, reclaims ethanol to there not being the alcohol flavor, be equivalent to crude drug 4g/ml, cold preservation 24 hours;
Mix said extracted liquid, stir evenly, add 5 times water of about Radix Aconiti Lateralis Preparata crude drug amount,, stir evenly, add 0.5% active carbon heated and boiled 20-60 minute, put coldly, add to 5 times water of Radix Aconiti Lateralis Preparata crude drug amount with mannitol 3%, accent PH to 5-7, fine straining, packing, lyophilization, promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02149368 CN1270739C (en) | 2002-11-13 | 2002-11-13 | Freeze drying powder containing red ginseng and accessory piece for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02149368 CN1270739C (en) | 2002-11-13 | 2002-11-13 | Freeze drying powder containing red ginseng and accessory piece for injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1500518A true CN1500518A (en) | 2004-06-02 |
| CN1270739C CN1270739C (en) | 2006-08-23 |
Family
ID=34233622
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02149368 Expired - Lifetime CN1270739C (en) | 2002-11-13 | 2002-11-13 | Freeze drying powder containing red ginseng and accessory piece for injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1270739C (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007074B (en) * | 2006-01-25 | 2011-08-10 | 天津天士力之骄药业有限公司 | Preparing method of Ginseng and Aconite preparation for injection |
| CN102920797A (en) * | 2012-11-15 | 2013-02-13 | 沈阳药科大学 | Extraction and purification process for active components of kusnezoff monkshood |
-
2002
- 2002-11-13 CN CN 02149368 patent/CN1270739C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101007074B (en) * | 2006-01-25 | 2011-08-10 | 天津天士力之骄药业有限公司 | Preparing method of Ginseng and Aconite preparation for injection |
| CN102920797A (en) * | 2012-11-15 | 2013-02-13 | 沈阳药科大学 | Extraction and purification process for active components of kusnezoff monkshood |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1270739C (en) | 2006-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101116722A (en) | Pharmaceutical formulations with the raw material containing panax, ophiopogon root and schisandra fruit, processes for their preparation, the raw material and the quality control method for the prepa | |
| CN1349818A (en) | Effective part group in red sage mixture and its delayed release prepn. medicinal use and prepn process | |
| CN1270739C (en) | Freeze drying powder containing red ginseng and accessory piece for injection | |
| CN101049438A (en) | Composition of Chinese traditional medicine for treating coronary heart disease | |
| CN100484557C (en) | Chinese medicine compound preparation for treating myocardial ischemia and improving microcirculation, and preparing method thereof | |
| CN101884661A (en) | Traditional Chinese medical preparation containing leeches and astragalus and used for treating cardiovascular and cerebrovascular diseases | |
| CN101856389A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and application thereof | |
| CN100431566C (en) | Chinese medicine composition and its prepn process and application | |
| CN107569528A (en) | A kind of pharmaceutical composition for treating hepatitis, pharmaceutical preparation and application and preparation method | |
| CN1745795A (en) | Medicine for preventing and treating coronary heart disease and preparation method thereof | |
| CN102861232A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating hypertension | |
| CN103027944A (en) | Pharmaceutical composition for preventing and treating cardiovascular and cerebrovascular disease | |
| CN100448457C (en) | Effective position of pilose asiabell root, preparation, medication use and preparation method | |
| CN102861231B (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating ventricular remodeling after myocardial infarction | |
| CN107343925B (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
| CN101199568A (en) | Medicament compound for treating cardiovascular disease and preparing method thereof | |
| CN1857442A (en) | Preparation and application of ligustrazine and its salt composition | |
| CN1182862C (en) | Chinese medicine prepn for treating coronary heart disease and angina pectoris and its prepn | |
| CN101095715A (en) | Cardiac and cerebral vascular disease treating medicine composition | |
| CN1985881A (en) | Preparing process and application of compound red sage and chuanxiong rhizome oral preparation | |
| CN1239164C (en) | Haw effective part and its extracting method and uses | |
| CN1377688A (en) | Extracting process for decoction of poria, Bighead Atractylodes, cinnamom and Lirorice and its medicinal use | |
| CN116211945B (en) | Traditional Chinese medicine composition, preparation method thereof and application thereof in preparation of medicine for treating or preventing chronic cerebral circulation inefficiency | |
| CN1212121C (en) | Product of ginsenoside for curing hepatitis | |
| CN1506079A (en) | Diabetes treating medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 625000 No. 116 West South Street, Sichuan, Ya'an Patentee after: SANJU MEDICAL & PHARMACEUTICAL CO.,LTD. Address before: 625000 No. 116 West South Street, Sichuan, Ya'an Patentee before: Yaan Sanjiu Pharmaceutica Co.,Ltd. |
|
| CX01 | Expiry of patent term |
Granted publication date: 20060823 |
|
| CX01 | Expiry of patent term | ||
| DD01 | Delivery of document by public notice |
Addressee: Li Yanting Document name: Notice of Expiration and Termination of Patent Right |
|
| DD01 | Delivery of document by public notice |